(RTTNews) - Accenture (ACN) said it has invested, through Accenture Ventures, in Iridius, an enterprise AI infrastructure company that designs compliant-by-design AI solutions for highly regulated industries, including life sciences and pharmaceuticals sectors. Accenture and Iridius will also form a strategic partnership to support life sciences organizations in scaling AI adoption. Terms of the investment were not disclosed.
Accenture and Iridius will build end-to-end compliance workflows across the life sciences value chain, from regulatory submissions and pharmacovigilance to clinical and manufacturing operations.
At last close, Accenture shares were trading at $178.28, down 6.22%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
